AQR Capital Management
IPSC icon

AQR Capital Management’s Century Therapeutics IPSC Stock Holding History

AQR Capital Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,660
Closed -$5.31K – 3605
2025
Q3 		$5.31K Sell
10,660
-136,508
-93% -$73.6K ﹤0.01% 3456
2025
Q2 		$82.2K Buy
147,168
+36,089
+32% +$19.4K ﹤0.01% 3211
2025
Q1 		$52.9K Buy
111,079
+86,875
+359% +$65.3K ﹤0.01% 3079
2024
Q4 		$24.4K Buy
24,204
+3,343
+16% +$4.55K ﹤0.01% 2841
2024
Q3 		$35.7K Buy
+20,861
New +$40.9K ﹤0.01% 2723

Other funds holding IPSC

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AQR Capital Management's IPSC Position: Q4 2025 in Review

AQR Capital Management sold out of Century Therapeutics (IPSC) in Q4 2025, closing a stake of 10,660 shares — an estimated $5.31K sold.

AQR Capital Management first reported a position in IPSC in Q3 2024 and held it in 5 quarters. The position peaked at $82.2K in Q2 2025. 47 funds tracked by Wall St. Rank hold IPSC as of Q4 2025.

  • AQR Capital Management reported no remaining Century Therapeutics position as of Q4 2025 after selling out during the quarter.
  • AQR Capital Management sold 10,660 Century Therapeutics shares in Q4 2025, an estimated $5.31K.
  • AQR Capital Management first reported a position in Century Therapeutics in Q3 2024 and held it in 5 quarters.
  • AQR Capital Management's Century Therapeutics position peaked at $82.2K in Q2 2025.
  • 47 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2025.

Based on AQR Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.